A 6-month multicenter, single-arm, open-label study to investigate changes in biomarkers after initiation of treatment with 0.5 mg fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis
- Registry ID
- EUCTR2010-022066-28
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Novartis Pharma GmbH
- Start date
- 2010-10-27
- Completion date
- 2012-07-11
- Last update
- 2026-08-16
Conditions
- relapsing remitting Multiple Sclerosis
Summary
The primary endpoints are the reduction of CD4+ and CD8+ naïve T cells (CCR7+CD45RA+), central memory T cells (CCR7+CD45RA-), central memory Th17 cells (CD4+ CCR4+ and CCR6+), and an elevation of effector memory T cells (CCR7- CD45RA-) in peripheral venous blood at month 6 versus baseline.
Locations
View on source registry